Hexamer Therapeutics
Hexamer Therapeutics is focused on developing innovative vaccine technologies, including rapid, scalable, and natural peptide-based vaccines. Their mission is to create effective vaccines for COVID-19 variants, emerging infectious diseases, and cancer, utilizing proprietary platform technology combined with advanced AI. They aim to deliver safe, robust, and easily distributable vaccines, with a vision to revolutionize pandemic response and health security.
Industries
Nr. of Employees
small (1-50)
Hexamer Therapeutics
Products
Self-assembling peptide vaccine platform
A modular vaccine scaffold made from natural peptides that self-assembles and is designed to present conjugated antigenic targets with controlled stoichiometry; intended for rapid generation of vaccine candidates and combination antigen approaches.
SARS-CoV-2 vaccine candidates (peptide-based)
Vaccine candidates targeting SARS-CoV-2 S-protein regions using the peptide scaffold with demonstrated in vitro neutralization and preclinical antibody and T-cell responses.
Personalized neoantigen cancer vaccine development
Modular hapten/scaffold-based approach to create individualized vaccines that present patient-specific tumor neoantigens to stimulate anti-tumor immunity.
Self-assembling peptide vaccine platform
A modular vaccine scaffold made from natural peptides that self-assembles and is designed to present conjugated antigenic targets with controlled stoichiometry; intended for rapid generation of vaccine candidates and combination antigen approaches.
SARS-CoV-2 vaccine candidates (peptide-based)
Vaccine candidates targeting SARS-CoV-2 S-protein regions using the peptide scaffold with demonstrated in vitro neutralization and preclinical antibody and T-cell responses.
Personalized neoantigen cancer vaccine development
Modular hapten/scaffold-based approach to create individualized vaccines that present patient-specific tumor neoantigens to stimulate anti-tumor immunity.
Services
Collaborative vaccine development partnerships
Partnerships to co-develop and manufacture peptide-based vaccines using the self-assembling scaffold and partner cGMP peptide manufacturers.
Collaborative vaccine development partnerships
Partnerships to co-develop and manufacture peptide-based vaccines using the self-assembling scaffold and partner cGMP peptide manufacturers.
Expertise Areas
- Peptide-based vaccine platform development
- Rapid vaccine candidate engineering
- Antigen conjugation chemistry for epitope presentation
- Preclinical immunology and neutralization assays
Key Technologies
- Self-assembling peptide scaffolds
- Antigen conjugation with stoichiometric control
- Synthetic/cGMP peptide manufacturing
- Lyophilization for dry-powder vaccines